Status: Recruiting
Switch to Dolutegravir Plus Lamivudine Dual-Therapy in Transgender Women Living With HIV on Virologically Suppressive Antiretroviral Therapy (TRANS-SWITCH)
This single-arm, open label study is aimed to assess efficacy and safety of dolutegravir plus lamivudine as a switch strategy among TGW with HIV receiving suppresive antiretroviral therapy.
Participants needed: 50
Trial details
Phase: Phase 4Age: 18+Biological sex: MaleType: InterventionalSponsor: UBATECUpdated: Sep 12, 2025Locations: 1
Eligibility criteria
18 years or older at the time of signing the informed consent. [+8]
History or presence of hypersensitivity to any of the study drugs or their compo... [+13]